Sanofi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SANOFI, and what generic alternatives to SANOFI drugs are available?
SANOFI has one hundred and twenty-seven approved drugs.
There are eleven US patents protecting SANOFI drugs.
There are two hundred and thirty-seven patent family members on SANOFI drugs in fifty-two countries and one hundred and twenty-two supplementary protection certificates in nineteen countries.
Summary for Sanofi
| International Patents: | 237 |
| US Patents: | 11 |
| Tradenames: | 101 |
| Ingredients: | 89 |
| NDAs: | 127 |
| Patent Litigation for Sanofi: | See patent lawsuits for Sanofi |
| PTAB Cases with Sanofi as petitioner: | See PTAB cases with Sanofi as petitioner |
Drugs and US Patents for Sanofi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | PERTOFRANE | desipramine hydrochloride | CAPSULE;ORAL | 013621-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Sanofi Aventis Us | ARALEN | chloroquine phosphate | TABLET;ORAL | 006002-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Sanofi Aventis Us | DANOCRINE | danazol | CAPSULE;ORAL | 017557-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Sanofi Aventis Us | BRONKOSOL | isoetharine hydrochloride | SOLUTION;INHALATION | 012339-008 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Sanofi Aventis Us | TALACEN | acetaminophen; pentazocine hydrochloride | TABLET;ORAL | 018458-001 | Sep 23, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Sanofi Aventis Us | TENUATE | diethylpropion hydrochloride | TABLET;ORAL | 017668-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Sanofi Aventis Us | OFORTA | fludarabine phosphate | TABLET;ORAL | 022273-001 | Dec 18, 2008 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sanofi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | KERLEDEX | betaxolol hydrochloride; chlorthalidone | TABLET;ORAL | 019807-002 | Oct 30, 1992 | 4,311,708 | ⤷ Sign Up |
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | TABLET;ORAL | 014214-002 | Approved Prior to Jan 1, 1982 | 3,590,036 | ⤷ Sign Up |
| Sanofi | RENVELA | sevelamer carbonate | TABLET;ORAL | 022127-001 | Oct 19, 2007 | 5,496,545 | ⤷ Sign Up |
| Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-007 | Jun 2, 2000 | 4,486,420 | ⤷ Sign Up |
| Sanofi Aventis Us | ARAVA | leflunomide | TABLET;ORAL | 020905-002 | Sep 10, 1998 | 4,351,841 | ⤷ Sign Up |
| Sanofi Aventis Us | DIABETA | glyburide | TABLET;ORAL | 017532-001 | May 1, 1984 | 4,060,634 | ⤷ Sign Up |
| Sanofi Aventis Us | ARAVA | leflunomide | TABLET;ORAL | 020905-001 | Sep 10, 1998 | 4,351,841 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANOFI drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 7 mg and 14 mg | ➤ Subscribe | 2016-09-12 |
| ➤ Subscribe | Capsules | 0.4 mg | ➤ Subscribe | 2004-12-20 |
| ➤ Subscribe | Tablets | 300 mg/25 mg | ➤ Subscribe | 2006-06-06 |
| ➤ Subscribe | Injection | 2 mcg/mL, 2 mL ampules | ➤ Subscribe | 2007-10-15 |
| ➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2013-07-01 |
| ➤ Subscribe | Injection | 2 mcg/mL, 1 mL in 2 mL vial | ➤ Subscribe | 2011-12-28 |
| ➤ Subscribe | Powder for Oral Suspension | 0.8 g/packet and 2.4 g/packet | ➤ Subscribe | 2009-12-30 |
| ➤ Subscribe | Injection | 5 mg/mL, 10 mL and 20 mL vials | ➤ Subscribe | 2007-02-09 |
| ➤ Subscribe | Injection | 200 mg/40 mL | ➤ Subscribe | 2007-07-16 |
| ➤ Subscribe | Injection | 100 mg/mL, 3 mL vials | ➤ Subscribe | 2006-12-07 |
| ➤ Subscribe | Extended-release Tablets | 12.5 mg | ➤ Subscribe | 2006-01-19 |
| ➤ Subscribe | Tablets | 150 mg/12.5 mg and 300 mg/12.5 mg | ➤ Subscribe | 2004-11-10 |
| ➤ Subscribe | Capsules | 0.5 mcg and 2.5 mcg | ➤ Subscribe | 2009-03-25 |
| ➤ Subscribe | Tablets | 75 mg, 150 mg and 300 mg | ➤ Subscribe | 2004-05-25 |
| ➤ Subscribe | Capsules | 1 mcg | ➤ Subscribe | 2010-02-12 |
| ➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-03-04 |
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2008-12-04 |
| ➤ Subscribe | Injection | 40 mg/mL, 0.5 mL and 2 mL vials | ➤ Subscribe | 2009-06-30 |
| ➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2007-02-09 |
| ➤ Subscribe | Injection | 5 mg/mL, 40 mL vial | ➤ Subscribe | 2011-03-23 |
| ➤ Subscribe | Extended-release Tablets | 6.25 mg | ➤ Subscribe | 2006-02-24 |
International Patents for Sanofi Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101712231 | ⤷ Sign Up |
| European Patent Office | 1935416 | ⤷ Sign Up |
| Peru | 20091809 | ⤷ Sign Up |
| South Korea | 20100135909 | ⤷ Sign Up |
| Tunisia | 2010000454 | ⤷ Sign Up |
| Dominican Republic | P2012000070 | ⤷ Sign Up |
| Uruguay | 31768 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sanofi Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0680967 | SPC/GB02/001 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TELITHROMYCIN AND ADDITION SALTS THEREOF WITH PHARMACEUTICALLY ACCEPTABLE ACIDS; REGISTERED: UK EU/1/01/191/001-004 20010710 |
| 3300601 | 22C1034 | France | ⤷ Sign Up | PRODUCT NAME: COMBINAISON DE DAUNORUBICINE ET CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
| 1007030 | SPC/GB10/029 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DRONEDARONE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/09/591/001 20091126; UK EU/1/09/591/002 20091126; UK EU/1/09/591/003 20091126; UK EU/1/09/591/004 20091126 |
| 1667986 | SPC/GB13/042 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: CABAZITAXEL IN THE FORM OF THE ACETONE SOLVATE; REGISTERED: UK EU/1/11/676/001 20110317 |
| 2768484 | 2019041 | Norway | ⤷ Sign Up | PRODUCT NAME: KOMBINASJON AV DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180831 |
| 0502314 | SPC/GB02/037 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
| 1667986 | 1390025-3 | Sweden | ⤷ Sign Up | PRODUCT NAME: CABAZITAXEL ACETONSOLVAT; REG. NO/DATE: EU/1/11/676/001 20110317 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
